WHO ICTRP trial
In-Vivo Bioequivalence study of Naltrexone intramuscular injection in healthy…
IRCT20200105046010N22 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200105046010N22 |
|---|---|
| Public title | In-Vivo Bioequivalence study of Naltrexone intramuscular injection in healthy Iranian volunteers |
| Scientific title | In-Vivo Bioequivalence study of Naltrexone intramuscular injection 380mg of Nano Daru Pajouhan Pardis (EXOPIO® 380mg) with brand drug (VIVITROL® 380mg, Alkermas Pharma, Ireland). |
| Primary sponsor | Nano Pajhoohan Pardis Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | bioequivalence of test and reference drugs. |
| Interventions | Intervention 1: The intervention group: receives one test ampoule (Exopio of Nano Daroo Pajohan Pardis Pharmaceutical Company Contains 380 mg of naltroxane) as intramuscular injection. Blood samples were taken from the volunteers for 1… |
| Registration date | Jan 19, 2021 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: